相关实验视频

Updated: May 22, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

双重CAR-T细胞疗法:最近的进展和当前的挑战

Sara Gómez-Melero^1,2, Fakhri Hassouneh¹, Isabel M Vallejo-Bermúdez¹

¹Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain.

Frontiers in immunology

|March 17, 2025

概括

双联CAR-T细胞提供了一个有希望的策略,以克服当前癌症治疗的局限性,如抗原损失. 进一步的研究是必要的,以优化这一创新疗法,以改善患者的治疗结果.

科学领域:

免疫治疗是一种免疫疗法.
在瘤学瘤学.
细胞疗法细胞疗法

背景情况:

化学抗原受体T (CAR-T) 细胞疗法已经改变了癌症治疗.
临床挑战仍然存在,包括抗原损失和低于最佳的CAR设计.

研究的目的:

审查多目标CAR-T疗法的潜力,特别是双联CAR-T细胞.
总结关于双联CAR-T细胞疗效和安全的临床前和临床研究结果.

主要方法:

审查现有的临床前和临床研究对合CAR-T细胞疗法.
对有关疗效,安全性和复发率的数据进行分析.

主要成果:

双体CAR-T细胞在血液性恶性瘤和固体瘤中显示出有前途的疗效和安全性.
与传统的CAR-T细胞相比,这些疗法的复发率相对较低.

结论:

双体CAR-T细胞代表了CAR-T细胞疗法的重大进步.
进一步的研究对于完善CAR构造,目标选择和转导效率至关重要,以提高效率.

关键词:

抗原逃逸的方法是什么?癌症癌症癌症癌症癌症仿制性抗原受体的仿制性抗原受体双接收器双接收器是什么意思免疫疗法免疫疗法多个目标多个目标.

更多相关视频

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.